Skip to main content

Grisactin Ultra Side Effects

Generic name: griseofulvin

Medically reviewed by Last updated on Aug 23, 2023.

Note: This document contains side effect information about griseofulvin. Some dosage forms listed on this page may not apply to the brand name Grisactin Ultra.

Applies to griseofulvin: oral suspension, oral tablet.

Serious side effects of Grisactin Ultra

Along with its needed effects, griseofulvin (the active ingredient contained in Grisactin Ultra) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking griseofulvin:

More common

Less common


Incidence not known

Other side effects of Grisactin Ultra

Some side effects of griseofulvin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

Incidence not known

For Healthcare Professionals

Applies to griseofulvin: compounding powder, oral capsule, oral suspension, oral tablet.

Nervous system

Very common (10% or more): Headache (up to 15%)

Uncommon (0.1% to 1%): Impaired coordination, peripheral neuropathy, confusion, dizziness, drowsiness, taste sensation changes

Frequency not reported: Peripheral neuritis, lethargy, mental confusion, impairment of performance of routine activities/efforts, vertigo, neuropathy, paresthesia of the hands and feet[Ref]

Headache was sometimes severe and usually disappeared during continued therapy.

Neuropathy and paresthesia have been reported in a few cases of long-term therapy with this drug. In 1 woman, paresthesia reportedly developed in the fingers and feet after 6 months of therapy. Neuropathy progressed for 4 months after the drug was discontinued but resolved 8 months after therapy was discontinued.[Ref]


Common (1% to 10%): Diarrhea, nausea, vomiting, gastric discomfort

Frequency not reported: Heartburn, flatulence, gastrointestinal bleeding, epigastric distress, oral thrush, increased fecal protoporphyrins[Ref]

A moderate but inconsistent increase of fecal protoporphyrins has been observed when this drug was used for a prolonged duration.[Ref]


Uncommon (0.1% to 1%): Toxic epidermal necrolysis, erythema multiforme, photosensitivity (on exposure to intense natural/artificial sunlight)

Rare (0.01% to 0.1%): Bullous reactions (including Lyell's syndrome), urticarial reactions, skin rashes, severe angioedema

Frequency not reported: Cold and warm urticaria, erythema eruptions, vesicular eruptions, morbilliform eruptions, fixed-drug eruptions, lesions (on sun-exposed areas), bullous eruption

Postmarketing reports: Severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), erythema multiforme[Ref]

At least 1 reported case of toxic epidermal necrolysis resulted in death.

Fixed-drug eruptions have been verified by rechallenge.

A patient with Hailey-Hailey disease (chronic benign familial pemphigus) experienced a widespread bullous eruption due to this drug.[Ref]


Uncommon (0.1% to 1%): Insomnia, irritability[Ref]


Uncommon (0.1% to 1%): Anorexia

Frequency not reported: Thirst, exacerbation of porphyria[Ref]


Rare (0.01% to 0.1%): Serum sickness syndromes

Frequency not reported: Hypersensitivity reactions (e.g., skin rashes, urticaria, erythema multiforme/erythema multiforme-like drug reactions, angioneurotic edema)[Ref]


Rare (0.01% to 0.1%): Hepatotoxicity

Very rare (less than 0.01%): Altered/elevated liver function tests, intrahepatic cholestasis, hepatitis

Frequency not reported: Elevated liver enzymes, hyperbilirubinemia

Postmarketing reports: Jaundice, elevated AST, elevated ALT, elevated bilirubin[Ref]

Liver function tests were elevated to greater than 3 times the upper limit of normal.[Ref]


Rare (0.01% to 0.1%): Leukopenia, neutropenia, anemia

Frequency not reported: Coagulopathy[Ref]

Leukopenia, neutropenia, and anemia generally resolved when therapy was stopped.[Ref]


Rare (0.01% to 0.1%): Precipitation of systemic lupus erythematosus, lupus-like syndromes, exacerbation of existing lupus

Frequency not reported: Drug-induced myositis[Ref]

At least 1 fatal case of systemic lupus erythematosus exacerbation occurred after ingestion of about 1 g of this drug.[Ref]


A patient developed interstitial nephritis after 1 year of therapy. The patient presented with renal insufficiency, hematuria, pyuria, eosinophiluria, and anemia. Renal function returned to normal after 1 year.[Ref]

Rare (0.01% to 0.1%): Nephrosis

Frequency not reported: Interstitial nephritis[Ref]


Rare (0.01% to 0.1%): Proteinuria, menstrual irregularities

Frequency not reported: Albuminuria (without evidence of renal dysfunction)[Ref]


A disulfiram-like reaction (including flushing, nausea, vomiting, diarrhea, paresthesia of the extremities) occurred in 1 patient who ingested this drug with alcohol.[Ref]

Frequency not reported: Fatigue, fever, disulfiram-like reaction[Ref]


1. Lecky BR (1990) "Griseofulvin-induced neuropathy." Lancet, 1, p. 230-1

2. "Product Information. Grifulvin V (griseofulvin)." Ortho McNeil Pharmaceutical

3. (2002) "Product Information. Fulvicin P/G (griseofulvin)." Schering Corporation

4. Gupta AK, Ryder JE (2003) "The use of oral antifungal agents to treat onychomycosis." Dermatol Clin, 21, 469-79, vi

5. Cerner Multum, Inc. "UK Summary of Product Characteristics."

6. Cerner Multum, Inc. "Australian Product Information."

7. Feinstein A, Sofer E, Trau H, Schewach-Millet M (1984) "Urticaria and fixed drug eruption in a patient treated with griseofulvin." J Am Acad Dermatol, 10, p. 915-7

8. Taylor B, Duffill M (1988) "Toxic epidermal necrolysis from griseofulvin." J Am Acad Dermatol, 19, p. 565-6

9. Boudghene-Stambouli O, Merad-Boudia A (1989) "Fixed drug eruption induced by griseofulvin." Dermatologica, 179, p. 92-3

10. Rustin MH, Bunker CB, Dowd PM, Robinson TW (1989) "Erythema multiforme due to griseofulvin." Br J Dermatol, 120, p. 455-8

11. Mion G, Verdon R, Le Gulluche YL, Carstein H, Garcia A, Guilbaud J (1989) "Fatal toxic epidermal necrolysis after griseofulvin." Lancet, 2, p. 1331

12. Meffert JJ, Davis BM, Campbell JC (1995) "Bullous drug eruption to griseofulvin in a man with hailey-hailey disease." Cutis, 56, p. 279-80

13. Miyagawa S, Sakamoto K (1989) "Adverse reaction to griseofulvin in patients with circulating anti-ssa/ro and ssb/la autoantibodies." Am J Med, 87, p. 99-102

14. Debruyne D, Coquerel A (2001) "Pharmacokinetics of antifungal agents in onychomycoses." Clin Pharmacokinet, 40, p. 441-72

15. Madhok R, Zoma A, Capell H (1985) "Fatal exacerbation of systemic lupus erythematosus after treatment with griseofulvin." Br Med J (Clin Res Ed), 291, p. 249-50

16. Miyagawa S, Okuchi T, Shiomi Y, Sakamoto K (1989) "Subacute cutaneous lupus erythematosus lesions precipitated by griseofulvin." J Am Acad Dermatol, 21, p. 343-6

17. Davidson BK (1995) "Myositis associated with griseofulvin therapy." Am Fam Physician, 52, p. 1277

18. Fett DL, Vukov LF (1994) "An unusual case of severe griseofulvin alcohol interaction." Ann Emerg Med, 24, p. 95-7

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.